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AIMS
To quantify the anti-inﬂammatory potency of topical corticosteroids and topical calcineurin inhibitors by measuring the contact
allergic response to a diphenylcyclopropenone (DPCP) challenge in de novo sensitized human volunteers.
METHODS
Two randomized, double-blind, vehicle-controlled studies were performed encompassing 76 volunteers: 29 in the ﬁrst and 47 in
the second study. Topical drugs were applied pre- and/or post-treatment in block designs. The compounds were tested simul-
taneously under occluded patch tests covering DPCP-induced dermatitis. Inhibitory responses were assessed by visual scoring and
measurements of the oedema thickness with ultrasound.
RESULTS
When applied both before and after the DPCP challenge, signiﬁcant anti-inﬂammatory effects were seen in descending order for
tacrolimus 0.1% ointment, clobetasol propionate ointment, betamethasone valerate ointment and hydrocortisone butyrate
ointment, while pimecrolimus cream, hydrocortisone ointment and vehicles had no signiﬁcant effect. Only tacrolimus ointment
(P < 0.01) demonstrated a consistent signiﬁcant pre-treatment inhibitory effect compared with an untreated DPCP control.
CONCLUSIONS
This human testing method in which the inﬂammation of experimentally induced allergic patch test reactions is quantiﬁed by
objective measurement allows an analysis of the anti-inﬂammatory potency of not only topical corticosteroids, but also of drugs
that have no effect on vasoconstriction. The method allowed comparison of the potencies of four topical corticosteroids and two
calcineurin inhibitors.
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WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT
• The potency of topical corticosteroids is determined by the human vasoconstrictor assay, which is a surrogate method for
anti-inﬂammatory effect.
• Human methods for testing the anti-inﬂammatory potency of topical corticosteroids are reported; however, there is no
standardized quantitative human test method for simultaneous testing of both corticosteroids and nonsteroidal drugs.
WHAT THIS STUDY ADDS
• These studies provide a standardized method for testing and comparing the anti-inﬂammatory potencies of topical
corticosteroids and calcineurin inhibitors in human volunteers.
Introduction
Corticosteroids are the major topical anti-inﬂammatory
drugs used in the treatment of a wide range of inﬂamma-
tory skin diseases. There is a need for new therapies and
for reliable human testing methods that allow the anti-
inﬂammatory potencies of topical corticosteroids to be
compared, as well to compare topical non-steroidal
anti-inﬂammatory drugs with topical corticosteroids. Tradi-
tionally, the potency of topical corticosteroids has been de-
termined using the human vasoconstrictor assay in which
cutaneous pallor is evaluated after occluded application of
agents on healthy skin [1]. This classical assay has inherent
limitations as follows: (i) the vasoconstrictor assay method-
ology relies primarily on the subjective nature of clinical
inspection to estimate the blanching effect; (ii) it uses the
degree of skin blanching as an indicator of drug potency
and, as such, only functions as a surrogate assessment of
the anti-inﬂammatory effect; and (iii) it is not possible to
compare the effect of topical corticosteroids with nonste-
roidal therapies such as topical calcineurin inhibitors,
which have no vasoconstrictor activity [2, 3]. At present,
tacrolimus and pimecrolimus are only approved for the
treatment of atopic dermatitis; however, there is evidence
to support their efﬁcacy in the treatment of other types
of eczema including seborrheic dermatitis and allergic con-
tact dermatitis [4–8]. Several studies have compared the
therapeutic potency of topical corticosteroids by assessing
their effects on allergic reactions elicited by environmental
allergens such as nickel or poison ivy in spontaneously
sensitized patients [2, 9–13], while use of a standardized
immunological challenge with an experimental sensitizer,
dinitrochlorobenzene (DNCB), in healthy volunteers has
only been reported once as a tool to quantify the potency
of anti-inﬂammatory agents [3].
To develop a human testing method to quantify the rela-
tive potencies of topical anti-inﬂammatory drugs, we chose
diphenylcyclopropenone (DPCP) as the experimental aller-
gen. We recently showed that following sensitization of
healthy volunteers with DPCP, reactivity to repeated chal-
lenges with DPCP initially became progressively stronger,
but following the second epicutaneous challenge, the re-
sponses become stable and reproducible as assessed by both
visual scoring and as measured by skin fold thickness [14].
This clinical ﬁnding was supported by histopathology and
immunohistochemistry staining together with microarray
gene expression proﬁling using skin biopsies taken from
DPCP-challenged sites [15].
We aimed to develop a human testing method for a T-cell
mediated inﬂammatory process in the form of a quantiﬁed
and standardized allergic contact hypersensitivity response,
to evaluate the relative potencies of a variety of topical
anti-inﬂammatory drugs. We designed the study so that the
inﬂammatory challenge used for testing anti-inﬂammatory
effects was not too aggressive and therefore had the best
chance of revealing weaker drug effects. This was achieved
by pretesting volunteers to determine the ability of the DPCP
challenge concentrations to elicit measurable inﬂammatory
responses. We also wanted to compare the sensitivity of the
test system to detect potency differences when the agents
were applied before or after the DPCP challenge, or were ap-
plied both before and after the challenge. We performed
two randomized, double blind, vehicle-controlled studies in
which tacrolimus, pimecrolimus and four topical corticoste-
roids of different strengths/potencies were compared in ran-
domized block designs.
Methods
Volunteers
Healthy volunteers were recruited by advertising on internal
notice boards. Twenty-nine volunteers participated (13
women and 16 men, aged 20–43 years, median 25 years) in
study I, and 47 volunteers (16 women and 31 men, aged
20–44 years, median 26 years) in study II. Participants com-
prised two different groups; pre-sensitized volunteers (n = 5)
from a previous DPCP study [14, 15] and ﬁrst-time volunteers
(Study I: n = 24; Study II: n = 23). Informed consent was ob-
tained from all participants. Exclusion criteria included the
following: (i) active skin disease; (ii) a history of atopic derma-
titis; (iii) endocrine or immune system disorders; (iv) preg-
nancy or breastfeeding; and (v) active or prior (i.e. 30 days
before study inclusion) treatment with UV radiation,
systemic/topical corticosteroids or other immunosuppressive
agents that might inﬂuence the treatment response. The
studies were approved by the Regional Scientiﬁc Ethical Com-
mittees for Southern Denmark (Study-ID: S-20140149 and
S-20130074) and conducted in accordance with the Helsinki
declaration.
Induction of DPCP contact allergy
Induction of allergic sensitivity was performed using a single
DPCP dose of 30 μg cm–2 (22.8 μl of 0.125%DPCP in acetone)
applied to a ﬁlter-paper-lined, 12-mm Finn chamber
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(SmartPractice, Phoenix, AZ, USA). The patch test chamber
was attached to the skin on the upper buttock then left in
place for 48 h [16]. Presensitized volunteers (n = 5) from a pre-
vious DPCP study [14, 15] and all participants in studies I and
II were sensitized using the same sensitization protocol. All
DPCP (CAS no. 886–38-4; Alfa Aesar, Karlsruhe, Germany) so-
lutions used in the study were provided by Central Pharmacy,
Odense University Hospital.
The initial elicitation challenge
The initial elicitation challenge was carried out four weeks af-
ter the induction phase. Volunteers received a DPCP dose se-
ries consisting of seven doses (dose per unit areas) that were
increased in 60% increments: 0.484, 0.774, 1.24, 1.98, 3.17,
5.1 and 8.12 μg cm–2. The DPCP doses were applied to ﬁlter-
paper-lined 8-mm Finn chambers as 10 μl of the appropriate
concentration in acetone to give the required dose-range. A
(negative) control of acetone only was also applied in a sepa-
rate patch test chamber. The patch test chambers were loaded
immediately before their attachment to the upper back. The
elicitation patches were removed after 6 h and the patch test
sites were marked with a skin marker. At 24 and 48 h, the elic-
itation responses were assessed visually and by skin ultra-
sound. In study I, two consecutive DPCP doses were selected
for each volunteer at the ﬁnal (48-h) reading. This was done
to: (i) ensure that a clinically detectable and quantiﬁable de-
gree of DPCP reactivity was elicited in the subsequent topical
treatment phase; and (ii) examine the inhibitory effects of
topical treatments on patch test reactions of different inﬂam-
matory levels elicited by lower versus higher DPCP doses.
Based on the ﬁndings from study I, we selected a single DPCP
dose in study II for each volunteer that elicited a patch test re-
action, corresponding to a doubtful/weak positive reaction or
higher, at the ﬁnal (48-h) visual reading.
Study designs
Both studies were conducted as randomized, double-blind,
vehicle-controlled trials comprising four phases as follows:
(i) induction of DPCP contact allergy in ﬁrst-time volunteers;
(ii) initial elicitation challenge with a DPCP dose series to de-
termine the desired dose (i.e. a mild to moderate positive re-
action) to be used in the drug treatment phase; (iii) topical
drug treatment of DPCP-induced allergic patch test reactions;
and (iv) visual scoring and skin ultrasound measurement of
test sites at 48 and 72 h. The placement of test drugs was ro-
tated (randomized) between volunteers.
In study I, 3 topical corticosteroid ointments were evalu-
ated in comparison with a negative control [i.e. an occluded
(empty) patch test chamber] and vehicle ointment on both
sides of the upper back in each individual. A randomized
complete block design was applied for this study.
In study II, the anti-inﬂammatory effect of six topical
agents was evaluated using a similar patch test method, and
in comparison with an untreated (positive) DPCP control,
negative control, and vehicle ointment and cream. The num-
ber of DPCP patches on each volunteer was limited to six on
each side of the upper back; therefore, due to the increased
number of tested agents, a balanced incomplete block design
was applied for this study.
Visual scoring
An extended version of the International Contact Dermatitis
Research Group scoring scale was used (Table 1) [17]. The re-
sponses were graded as negative (–), doubtful (?+), weak posi-
tive (1+), deﬁnite positive (2+), strong positive (3+) or
extremely strong positive (4+).
Skin ultrasound
High-resolution (20 MHz) skin ultrasound measurements of
patch test reactions were done using the DermaLab (SkinLab)
Combo Instrument (Cortex Technology, Hadsund,
Denmark). The ultrasound image contains a speciﬁc curve
(a super A-scan), which describes the total intensity of the
scanned skin area as a function of the depth into the skin.
The full ultrasound image is composed of the accumulated
average of 188 A-scans. The average thickness of the dermis
was calculated based on the super A-scan. Dermal inﬂam-
mation was determined by recording two dermal thickness
scans at each test site at both 48 h and 72 h after treatment
(Figure 1). The means of the two dermal thickness measure-
ments were used in the data analysis. For all recordings,
the same operating conditions were used for all volunteers.
Treatment of DPCP-induced allergic contact
dermatitis with test drugs
Study I assessed the effects of the topical anti-inﬂammatory
drugs applied after removal of the DPCP challenge (post-
treatment) because this mimics normal use in clinical
practice. Volunteers were rechallenged 5 days after the initial
elicitation challenge on either side of the upper back with the
two consecutive DPCP doses that had elicited mild to moder-
ate reactions in the ﬁrst challenge. These two doses were ap-
plied in two separate panels, each containing four patches
and a vehicle (acetone) control patch. The DPCP doses were
applied to ﬁlter-paper-lined, 8-mm Finn chambers and were
attached to the skin for 6 h. After removal, elicitation sites
were marked with a skin marker. Large (12-mm) Finn cham-
bers were then loaded with approximately 45 mg (corre-
sponding to a dose per area of ≈ 40 mg cm–2) ointment and
placed as a treatment to three of the highlighted
Table 1
Modiﬁed version of the International Contact Dermatitis Research
Group clinical scoring system
Symbol
Numerical
value Morphology
- 0 Negative reaction
?+ 1 Doubtful reaction; faint erythema only
1+ 2 Weak positive reaction; erythema with no
inﬁltration, possibly papules
2+ 3 Deﬁnite positive reaction; erythema,
inﬁltration, follicular papules, no vesicles
3+ 4 Strong positive reaction; intense erythema,
inﬁltration and vesicles
4+ 5 Extremely strong positive reaction;
coalescing vesicles and/or bullae
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elicitation/challenge sites, while the fourth DPCP elicitation
area was treated with a vehicle (white soft parafﬁn) patch.
The vehicle (acetone) control area was occluded with an
empty patch test chamber (i.e. negative control). All treat-
ment patches were removed after 48 h. The response at each
test site was assessed visually and measured with skin ultra-
sound immediately and after a further 24 h.
In study II, the anti-inﬂammatory effects of six topical
drugs (four corticosteroid ointments, tacrolimus 0.1% oint-
ment, pimecrolimus 1% cream, and vehicle ointment and
cream) were compared following pre-treatment alone and fol-
lowing combined pre- and post-treatment. The combined
pre- and post-treatment was used in order to maximize the
possible effect. The same patch test technique was used as de-
scribed for study I. Two panels were applied on each side of
the upper back (i.e. a left and right panel), each with six test
sites. According to the incomplete block design, the test sites
on each volunteer were pretreated for 24 h with four of the
topical products applied in duplicate in 12-mm Finn cham-
bers. In addition, four empty Finn chambers were applied.
All chambers were removed after 24 h and the test sites were
marked. Subsequently, the selected DPCP dose was applied
in ﬁlter-paper-lined, 8-mm Finn chambers and placed for
6 h on the eight pretreated sites and on two untreated sites.
The two remaining sites were occluded with empty Finn
chambers. After removal of the DPCP patches, the right panel
test sites were post-treated for 48 h with the same agents as
had been used for the pre-exposure treatment. The response
at each test site was assessed visually and measured with skin
ultrasound immediately and after a further 24 h. For volun-
teers who had participated in study I, the challenges were per-
formed on previously nonchallenged sites to avoid increased
reactivity at previous DPCP-challenged sites [18]. A ﬂow chart
and schematic diagrams illustrating the study designs are
shown in Figure 2.
Sample size
The sample size estimation was performed using the statisti-
cal software, SAS (software package: Proc Power, version 9.2,
SAS Institute Inc., Cary, NC, USA). Sample size estimation
was performed using a two-tailed paired t test and a level of
signiﬁcance of 0.05. Skin ultrasound was used as the primary
measurement variable. In study I, a randomized complete
block design was chosen, and a sample size of 24 volunteers
was required to achieve 90% power and enabling detection
of a 0.3-mm mean treatment difference based on a standard
deviation of 0.3 mm. In study II, because of the larger number
of test drugs included and to limit the number of DPCP
patches on each volunteer, a balanced incomplete block de-
sign was chosen [19]. The parameters of the balanced incom-
plete block design were: t (total number of treatments) = 8, b
(number of blocks) = 14, k (block size) = 4, and r (number of
repetitions) = 3. The design contained 4 × 14 = 56
subexperiments and had a relative efﬁcacy (variance of
pairwise comparison) of 0.86 corresponding to a complete
block design with 56/0.86 = 65 subexperiments. To achieve
the desired power equal to 24 × 8 = 192 subexperiments, the
Figure 1
Automated skin ultrasound measurements of dermal thickness in allergic contact dermatitis (ACD) and control reactions. The red left part of the
ultrasound curve shows the intensity of the ultrasound passing through the water chamber in the probe. The high left peak originates from the
combined ﬁlm/epidermal reﬂection. The red right part of the curve shows the intensity of the ultrasound passing through the subcutaneous layers.
The yellow part of the curve indicates the less reﬂective part of the dermis, while the green part indicates the more reﬂective part of the dermis. The
average thickness of the dermis is calculated based on the super A-scan. The dermal thickness measurements (in μm) are shown next to the ultra-
sound images (i.e. C and D) and represent the yellow and green part of the curves. (A) Ultrasound scan of ACD after Dermovate (clobetasol pro-
pionate) treatment at 72 h and (B) untreated (positive) diphenylcyclopropenone control scan at 72 h. Data from a participant in Study I are shown
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balanced incomplete block design had to be repeated (192/
65) three times. Hence, the total number of participants re-
quired for this study was 3 × 14 = 42.
Data and statistical analysis
Statistical analyses were performed with the statistical soft-
ware package GraphPad Instat (version 3.00, GraphPad Soft-
ware, San Diego, CA, USA). Experiments and data collection
were done by operators blinded to the treatment identity.
The blinding of treatments was broken after completion of
all tests. Visual scores were transformed to numerical values,
and non-parametric tests were applied for statistical analysis.
In study I, the visual scores were analysed globally using a
Friedman test, whereas a Kruskal–Wallis test was applied in
study II. In the case of global signiﬁcance, posthoc multiple
comparison tests (Dunn’s post-test in study I and Dunnett’s
post-test in study II) were further applied to examine values
between reference points [vehicle ointment in study I and
untreated (positive) DPCP control in study II] and each topi-
cal drug.
In study I, the skin thickness values of test areas treated
with drugs measured at 48 h and 72 h, respectively, were
expressed as percentages of the vehicle ointment value (ref-
erence point). Vehicle values were arbitrarily set at 100%. In
study II, untreated (positive) DPCP control was used as the
reference point instead of vehicle ointment due to the in-
complete block design. Skin thickness data were expressed
as a percentage of the absolute values at each time-point
in order to allow for accurate statistical analysis. One-way
Figure 2
Protocols for sensitization, challenges and topical drug treatment. (A) Flow chart (study I): Volunteers were sensitized on the upper buttock for
48 h. Four weeks later, an initial elicitation challenge (IEC) was performed with a diphenylcyclopropenone (DPCP) dose-series. After IEC, volun-
teers were rechallenged with two DPCP doses applied in two separate panels on the upper back followed by post-treatment with topical drugs.
(B) Flow chart (study II): The same setup was used as in study I except that after IEC, test sites were pretreated with four topical products on either
side of the upper back (left and right panel). This was followed by rechallenge with a select DPCP dose and ﬁnally post-treatment with topical
drugs. (C) Schematic setup of rechallenge and post-treatment with topical drugs (study I): The two panels each consisted of four small (8-mm) DPCP
patches (shown as vertical hatchings) and a vehicle (acetone) control patch (cross-hatching). Upon removal of these chambers, three large
(12-mm) chambers loaded with topical drugs (dotted rings), a large vehicle ointment chamber (solid ring), and a large empty (negative control)
chamber (dashed ring) were placed on the elicitation areas. (D) Schematic setup of pre-treatment, rechallenge, and combined pre- and post-treatment
with topical drugs (study II): The two pre-treatment panels each consisted of six test sites comprising four large Finn chambers ﬁlled with topical
drugs (dotted rings) and two empty chambers (dashed rings). Small (8-mm) DPCP chambers (vertical hatchings) were placed on the eight
pretreated sites and on two untreated sites. The two remaining sites were occluded with empty Finn chambers (cross-hatchings). The right panel
was post-treated with the same drugs as used for pre-treatment, again using large Finn chambers (dotted rings)
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analysis of variance with posthoc test (Dunnett’s post-test),
adjusted for multiple comparisons, was applied for the
ultrasound data. The level of signiﬁcance was set to
P < 0.05. The data and statistical analysis comply with the
recommendations on experimental design and analysis in
pharmacology [20].
Materials (topical anti-inflammatory agents)
The topical agents were: clobetasol propionate 0.5 mg g–1
ointment (Dermovate; GlaxoSmithKline Pharma, Brøndby,
Denmark), betamethasone-17-valerate 1 mg g–1 ointment
(Betnovate; GlaxoSmithKline Pharma, Brøndby, Denmark),
hydrocortisone-17-butyrate 1 mg g–1 ointment (Locoid;
Astellas Pharma, Kastrup, Denmark), hydrocortisone
10 mg g–1 ointment (Hydrocortisone DnE; Den Norske
Eterfabrikk, Oslo, Norway), tacrolimus 1 mg g–1 ointment
(Protopic; Astellas Pharma, Kastrup, Denmark) and
pimecrolimus 10 mg g–1 cream (Elidel; Meda, Allerød,
Denmark). Vehicle ointment [Apotekets Vaseline (Ph. Eur.);
Apotekernes Amba, Skovlunde, Denmark] and cream (Helo
creme; Faaborg Pharma, Faaborg, Denmark) were included.
The volunteers and investigators were blinded to all topical
agents and vehicles. The Central Pharmacy, Odense Univer-
sity Hospital, conducted the blinding and coding.
Results
Response to initial DPCP elicitation challenge
In study I, positive contact hypersensitivity to DPCP was in-
duced in 20 of 24 ﬁrst-time volunteers (sensitization rate: ≈
83%) based on the positive patch test responses at the initial
elicitation challenge. Of the ﬁve presensitized volunteers,
four responded to the dose series at the initial elicitation chal-
lenge; thus, 24 volunteers were included in the study. In
study II, sensitization to DPCP was obtained in 21 of 23
ﬁrst-time participants (sensitization rate: ≈ 91%). All
presensitized volunteers from study I responded to the dose-
series in the initial elicitation challenge; thus, 45 volunteers
participated in study II.
The anti-inflammatory effect assessed by
visual scoring
In the post-treatment study (study I), assessment by visual
scoring revealed a signiﬁcant anti-inﬂammatory effect for
clobetasol propionate and betamethasone valerate
(P < 0.001), while hydrocortisone was similar to vehicle.
The same degree of inhibitory effects of clobetasol propionate
and betamethasone valerate was found for both DPCP doses
(Table 2).
In study II, visual scoring of DPCP-induced reactions
pretreated with anti-inﬂammatory agents, only demon-
strated a signiﬁcant effect for tacrolimus 0.1% ointment at
48 h (P < 0.001) and at 72 h (P < 0.01) compared with un-
treated (positive) DPCP control. For DPCP-induced reactions,
which received both pre- and post-treatment, the three stron-
gest groups of steroids and tacrolimus showed the greatest
overall inhibition of response at 48 h (P < 0.001; Table 3).
The anti-inflammatory effect assessed by skin
ultrasound
In study I, signiﬁcant anti-inﬂammatory effects (P < 0.01)
were shown at both 48 h and 72 h for betamethasone valerate
and clobetasol propionate on challenge sites elicited by
higher DPCP doses. Betamethasone valerate and clobetasol
propionate reduced the inﬂammatory thickness up to 23.3%
and 22.5%, respectively. For lower DPCP doses, the anti-
inﬂammatory effects were less pronounced (Figure 3A, B).
In Study II (pre-treatment of DPCP challenge sites), the
anti-inﬂammatory effects of tacrolimus were signiﬁcant
(P < 0.01) at both 48 h and 72 h, with a 26% and 18%
reduction in the inﬂammatory thickness, respectively.
Betamethasone valerate (P < 0.05) displayed signiﬁcant inhi-
bition (11.5%) only at 48 h compared with untreated (posi-
tive) DPCP control. For combined pre- and post-treatment,
there was a signiﬁcant anti-inﬂammatory effect of tacrolimus
(28% reduction in inﬂammatory thickness at 48 h and 26.5%
at 72 h; P< 0.01), clobetasol propionate (28% at 48 h and 19%
at 72 h; P < 0.01), betamethasone valerate (22% at 48 h and
16% at 72 h; P < 0.01), and hydrocortisone butyrate (11% at
72 h; P < 0.01), while the effects of pimecrolimus and hydro-
cortisone were not signiﬁcant in this model (Figure 3C-F).
Table 2
Anti-inﬂammatory effect of topical drugs evaluated by visual scoring. Results 48 h and 72 h post-treatment [using lower and higher
diphenylcyclopropenone (DPCP) doses]
Post-treatment
Lower DPCP dose Higher DPCP dose
Vehicle/
Topical drug
48 h 72 h 48 h 72 h
Median Range P value Median Range P value Median Range P value Median Range P value
Vehicle ointment 3 0–5 - 3 1–5 - 3 2–5 - 3 2–5 -
Hydrocortisone 3 1–5 NS 3 0–5 NS 3 1–4 NS 3 1–5 NS
Betamethasone valerate 2 0–4 <0.001 2 0–4 <0.001 2 0–5 <0.001 2 1–4 <0.001
Clobetasol propionate 2 0–4 <0.001 2 0–4 <0.001 2 1–5 <0.01 2 0–4 <0.001
DPCP, diphenylcyclopropenone. P-values <0.05 are considered statistically signiﬁcant (NS = not signiﬁcant)
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Table 3
Anti-inﬂammatory effect of topical drugs evaluated by visual scoring. Pre-treatment results and combined pre- and 48 h and 72 h post-treatment
results
Pre-treatment Combined pre- and post-treatment
Positive DPCP/ Vehicle/
Topical drug
48 h 72 h 48 h 72 h
Median Range P value Median Range P value Median Range P value Median Range P value
Positive DPCP 3 1–5 - 3 1–5 - 3 2–5 - 3 2–5 -
Vehicle ointment 4 2–5 NS 3 2–4 NS 4 2–5 NS 3 2–4 NS
Vehicle cream 3 1–5 NS 3 1–5 NS 4 2–5 NS 3 2–5 NS
Hydrocortisone 3 2–5 NS 3 2–5 NS 4 1–5 NS 3 2–5 NS
Pimecrolimus 3 2–5 NS 3 2–5 NS 3 0–5 <0.05 3 0–5 NS
Hydrocortisone butyrate 3 1–5 NS 3 1–5 NS 2 0–5 <0.001 2 1–5 NS
Betamethasone valerate 3 0–5 NS 3 2–5 NS 2 1–5 <0.001 3 1–5 NS
Clobetasol propionate 3 2–5 NS 3 0–5 NS 2 0–4 <0.001 2 0–4 <0.01
Tacrolimus 1 0–3 <0.001 2 0–3 <0.01 0 0–3 <0.001 0 0–3 <0.001
P-values <0.05 are considered statistically signiﬁcant (NS = not signiﬁcant)
Figure 3
Anti-inﬂammatory effects of topical drugs evaluated by skin ultrasound. (A, B) Post-treatment at 48 h and 72 h using lower and higher
diphenylcyclopropenone (DPCP) doses; (C, D) pre-treatment at 48 h and 72 h; (E, F) combined pre- and post-treatment for 48 h and 72 h.
SEM: standard error of the mean; TCS: topical corticosteroids; TCIs: topical calcineurin inhibitors; Pc: pimecrolimus; Tc: tacrolimus; HC: hydrocor-
tisone; HCB: hydrocortisone butyrate; BV: betamethasone valerate; CP: clobetasol propionate. Asterisks indicate * P < 0.05 and **P < 0.01
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Discussion
These studies showed that an in vivo human model using an
inﬂammatory response driven by contact hypersensitivity
to DPCP succeeded in ranking the anti-inﬂammatory effect
of four topical corticosteroid ointment preparations and two
topical calcineurin inhibitors. Both visual assessment and ob-
jective measurement of DPCP induced skin inﬂammation
(skin ultrasound thickness) were used. Three modes of
application of the test drugs were explored; post-treatment,
pre-treatment, and combined pre- and post-treatment of
DPCP-induced allergic patch test reactions. Post-treatment
was used in the ﬁrst study; however, this study only revealed
a signiﬁcant anti-inﬂammatory effect for clobetasol propionate
and betamethasone valerate. In the second study, two calcine-
urin inhibitors were included in addition to the four corticoste-
roids. The only topical drug showing a signiﬁcant effect upon
pre-treatment was tacrolimus ointment, while the combined
pre-and post-treatment design was successful in ranking all
six products in the following order: tacrolimus 0.01% oint-
ment ≥ clobetasol propionate ointment ≥ betamethasone valer-
ate ointment ≥ hydrocortisone-17-butyrate ointment >
pimecrolimus cream= hydrocortisone ointment = vehicle oint-
ment and cream and untreated (positive) DPCP control.
DPCP elicited controlled, reliably reproducible, and ac-
ceptable degrees of allergic patch test reactions in sensitized
volunteers. There were no dropouts, and several volunteers
participated in 2–3 studies without noticeable adverse side ef-
fects. We have previously demonstrated that repeated DPCP
challenges in newly sensitized volunteers results in a clini-
cally reproducible and constant level of contact allergy mea-
sured by several in vivo and in vitro methods [14, 15]. This
constitutes the ethical and scientiﬁc basis for the possibility
of asking volunteers to participate in repeated tests for the
purpose of developing a human model for testing topical
anti-inﬂammatory drugs. Previous studies attempted to
develop appropriate in vivo models to assess the
anti-inﬂammatory effects of drugs using various types of in-
ﬂammatory challenges. Experiments in human volunteers
using skin irritants (e.g. nonanoic acid, sodium lauryl sul-
phate and sodium dodecyl sulphate) as model inﬂammatory
agents showed that irritant skin reactions cannot be used as
a tool in models testing the anti-inﬂammatory effects of top-
ical drugs [21–23]. Possible explanations for these failures in-
clude difﬁculty in standardization with regards to the choice
of irritant, determining an adequate irritant concentration
to elicit suitable irritant reactions, a pronounced interindi-
vidual variation in skin irritancy studies, and the lack of effect
of systemically administered prednisone on irritant patch
test reactions [21–25].
Several in vivomodels have been developed that aimed to
quantify the relative anti-inﬂammatory potencies of topical
corticosteroids using allergic hypersensitivity reactions elic-
ited by environmental allergens in spontaneously sensitized
patients. Most models used post-treatment application of
topical drugs because this represents the normal situation
for clinical usage.
Some studies have showed differences in the anti-
inﬂammatory effects of topical drugs on patch test reactions.
Alomar et al. [5] used visual scoring of nickel-induced contact
allergic reactions in a randomized, ointment-controlled,
double-blind study. It was shown that topical tacrolimus
0.1% and mometasone furoate 0.1% applied under occlusion
for 48 h as post-treatment had signiﬁcant inhibitory effects
[5]. Queille-Roussel et al. also used nickel-induced allergic re-
actions and reported that twice daily open application of
pimecrolimus 0.2% and 0.6% was superior to vehicle and
equal to betamethasone valerate 0.1% [4].
Only a few studies have used DNCB- and nickel-induced
allergic reactions to test the relative efﬁcacy and safety of
tacrolimus in vivo in humans by means of visual scoring
[7, 26, 27]. These studies showed that tacrolimus was more
effective than the corresponding vehicle in ameliorating al-
lergic reactions to nickel and DNCB, respectively [7, 26, 27].
Not only is tacrolimus effective in suppressing allergic skin
reactions in various animals and in man during the elicita-
tion phase [28, 29], there is also additional evidence to sug-
gest that it may be efﬁcacious when skin is treated before
elicitation of allergic reactions [26, 29]. This prechallenge
treatment effect may be explained on the basis that calcine-
urin inhibitors will exert signiﬁcant suppressive effects on
the cytokine response of resident memory T cells in the skin,
thereby reducing their capacity to initiate the inﬂammatory
process following exposure to an allergen [30, 31].
While the use of an experimental challenge with contact
allergens would seem to be a highly appropriate and relevant
form of inﬂammatory reaction for analysis of the anti-
inﬂammatory effects of drugs, use of spontaneously arising
contact allergies in humans presents problems. First, suitable
experimental subjects must be selected from the patient pop-
ulation who have spontaneous contact allergy to the desired
allergen. Secondly, the process of eliciting reproducible re-
sponses with an appropriate strength of response is not
straightforward. Many dose–response studies in nickel-
sensitive subjects have shown large intraindividual variation
in the threshold dose that elicits a positive patch test reac-
tion. The highest dose difference observed was 250-fold
[32]. Therefore, to obtain responses of similar intensity across
test subjects, it is necessary to perform similar prechallenges
to those we undertook. Thus, a prechallenge with a dose-
series could indicate the appropriate challenge doses to elicit
mild to moderate inﬂammatory responses. The advantage of
an experimental sensitizer such as DPCP is that it can be used
on all healthy human volunteers. DPCP is a strong sensitizer
that is able to sensitize virtually 100% of healthy humans.
Stable and reproducible responses to DPCP skin challenge de-
velop after the second exposure. By dose-titration, it is possi-
ble to elicit low level inﬂammation, which creates a suitable
inﬂammatory reaction to be able to discriminate between
the different topical anti-inﬂammatory drugs. Strong contact
hypersensitivity reactions present too big a therapeutic chal-
lenge for existing topical anti-inﬂammatory drugs, which re-
duces the possibility of revealing differences in their potency.
Another important aspect of the DPCP model is the short
application time (6 h) of the allergen challenge. This means
that the treatment with the drugs can be started before the re-
action is fully developed and increases the possibility of de-
tecting effects that inhibit the processes involved in
generating the inﬂammation. The main problem with initiat-
ing anti-inﬂammatory treatment 48 h after the activation of
the contact hypersensitivity response is that the reaction is
virtually fully developed by that time, so the task for the
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anti-inﬂammatory drugs is harder or possibly even different.
Our data show that the combination of pre- and post-
treatment augments the sensitivity of detection.
Because of the incomplete block design in study II, we
could not select vehicle ointment as a reference point as we
did in study I. It appears from Figure 3E and 3F that vehicle
(ointment and cream) enhanced the DPCP reactions, proba-
bly due to increased absorption.
This is the ﬁrst human in vivomodel that has succeeded in
comparing and ranking the anti-inﬂammatory potency of
various types of topical drugs, including both corticosteroids
and calcineurin inhibitors. The DPCP model in healthy vol-
unteers is a promising alternative to the vasoconstrictor assay,
which is only relevant for corticosteroids. Furthermore, the
traditional classiﬁcation of topical corticosteroids has been
questioned due to the fact that a strong vasoconstrictor effect,
as determined by the vasoconstrictor assay, is not necessarily
equivalent to a strong anti-inﬂammatory effect [33].
To increase the chances of the model being able to detect
more subtle differences between different active agents de-
sign modiﬁcations such as use of repeated applications of
the drugs under test may be introduced to allow for a cumula-
tive effect over time. Also, effects may be distinguished over
longer repetitive challenges; hence, combining repeated
DPCP exposures and drug applications could increase the
sensitivity. This has proven useful in a few studies with nickel
and tacrolimus [7, 27]. However, when several topical drugs
are compared in each individual, we consider that occluded
patches are needed to effectively control exposure.
In conclusion, the DPCP model developed here could de-
tect signiﬁcant anti-inﬂammatory effects for the three stron-
gest groups of corticosteroids and tacrolimus, and offers a
highly relevant alternative to the vasoconstrictor assay for
topical drug potency testing.
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